PAM16 and posterior cortical atrophy: Among the PCa patient cohort (n = 7792), all samples with high PAM16 expression (PCa PAM16 > 50th) from patients who received any clinically relevant anti-androgen therapy or chemotherapy at any point during treatment exhibited a shorter median OS (−9.146 months; HR = 1.219; 95% CI: 1.138–1.305; p < 0.00001) compared to patients with low PAM16 expression (PCa PAM16 < 50th) (Figure 7).